Influence of MMP on Brain AVM Hemorrhage
Influence of MMP on Brain AVM Hemorrhage
Brain vascular malformations, including arteriovenous malformations (AVM), cavernous
 malformations (CVM) and aneurysms, are a source of life-threatening risk of intracranial
 hemorrhage. The etiology and pathogenesis are unknown. There is no medical therapy presently
 available. Prevention of spontaneous intracerebral hemorrhage (ICH) is the primary reason to
 treat brain vascular malformations. The goal of this study is to: begin pilot studies to lay
 the groundwork for future clinical trials to develop medical therapy to decrease ICH risk.

 Matrix metalloproteinases (MMPs) regulate the extracellular matrix in association with
 various hemorrhagic brain disorders. MMP-9 has been most consistently associated with
 vascular wall instability and hemorrhagic brain disorders. Doxycycline, a non-specific MMP
 inhibitor, may enhance vascular stability, thus reducing the risk of spontaneous hemorrhage
 in brain vascular malformations by decreasing MMP-9 activity.
-  Doses will be randomized by the Pharmacy Department at UCSF for Doxycycline 100 mg/BID
 and Placebo BID. These will be prepared in blister-packs.

 -  Depending on enrollment/surgery date, patients will take medication either one to two
 weeks before surgery. Patients will be assigned to a treatment group according to a
 random table.

 -  Each patient will be initially provided with a 1 or 2-week supply of drug in blister
 packs. The patient will take the final dose of study drug on the morning of surgery.

 Baseline labs will be obtained and then again at time of surgery along with a piece of
 surgical tissue.
Inclusion Criteria:

 -  13 years or older

 -  Female patients of child bearing age using barrier-type birth control

 -  Creatinine no greater than 2.0 mg/di

 -  Alanine aminotransferase (ALT) no greater than 2 times upper limit of normal

 -  WBC count at least 3,800/mm3

 -  BMI within 50% of normal

 Exclusion Criteria:

 -  Allergy to tetracycline

 -  Unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days

 -  Female patients of child-bearing age not using effective birth control (barrier)

 -  History of vestibular disease (except benign positional vertigo)

 -  History of noncompliance with treatment or other experimental protocols

 -  Patients taking other antibiotics

 -  History of systemic lupus erythematosis

 -  Patients who are immunocompromised Patients with clinically significant hepatic
 dysfunction